SCHEDULE 13D/A: Nautilus Biotechnology Co-Founder Sujal Patel Boosts Stake to 15.7% with New Option Grant
Beneficial Ownership Amendment
Sujal Patel, co-founder of Nautilus Biotechnology, Inc., has increased his beneficial ownership in the company to 15.7% through direct holdings, a family trust, and a recent option grant.
Summary
- Sujal Patel, the Reporting Person, beneficially owns an aggregate of 20,297,732 shares of Nautilus Biotechnology, Inc. Common Stock.
- This ownership represents 15.7% of the Issuer's outstanding shares, calculated based on 126,148,469 shares outstanding as of February 21, 2025, plus 3,138,733 shares issuable from options held by Mr. Patel.
- Mr. Patel's holdings include 10,064,488 shares directly owned by him, 5,280,476 shares owned by PFV I, LLC (over which he has sole voting and dispositive power), and 1,814,035 shares held by the Sujal Patel 2020 Children's Trust (over which he shares voting and dispositive power with his spouse).
- He also holds options to purchase 3,138,733 shares of Common Stock, with 1,701,231 of these options exercisable within 60 days of March 3, 2025.
- On March 3, 2025, Mr. Patel was granted an option to purchase an additional 650,000 shares of the Issuer's Common Stock.
- Unvested options held by Mr. Patel are subject to immediate 100% vesting if his employment is terminated without cause or for good reason during a specific period around a change in control event.
- This filing is Amendment No. 2 to the original Schedule 13D filed on June 16, 2021, and previously amended on March 1, 2023.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive due to a co-founder increasing his stake and receiving additional stock options, which generally signals confidence in the company's future prospects. There are no negative financial or operational disclosures.
Positives
- Increased insider ownership by a co-founder and significant shareholder, Sujal Patel, potentially signaling strong confidence in the company's future.
- The grant of an additional 650,000 share options to Mr. Patel aligns his incentives with long-term shareholder value creation.
Risks
- The vesting of unvested options is accelerated upon certain termination events related to a change in control, which could dilute existing shareholders if such an event occurs and options are exercised.
Future Outlook
The document does not provide explicit forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing instead on beneficial ownership changes.
Industry Context
This filing reflects a significant insider's continued commitment to Nautilus Biotechnology, a company operating in the biotechnology sector. While not providing specific industry trends, increased insider ownership can be viewed positively within the biotech industry, which often requires long-term capital and development cycles.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Sujal Patel granted a Power of Attorney to several individuals, including company executives and legal counsel, to prepare, execute, and submit SEC filings (Forms 3, 4, 5, Schedules 13D, 13G, and Forms 144) on his behalf. | 2025-02-23 | Streamlines the process for Mr. Patel to comply with SEC reporting requirements related to his holdings in Nautilus Biotechnology, ensuring timely and accurate disclosures. |
Related Party Transactions
- Sujal Patel's beneficial ownership includes 1,814,035 shares held by the Sujal Patel 2020 Children's Trust, where he and his spouse share voting and dispositive power, indicating a related party holding.
- The grant of 650,000 share options to Sujal Patel on March 3, 2025, is a transaction between the company and a key insider/related party.
Stakeholder Impact
- Shareholders: Increased insider ownership may be viewed positively, suggesting alignment of interests between management and shareholders. The potential for dilution from accelerated option vesting upon a change in control is a consideration.
- Employees: The document does not directly impact employees beyond the reporting person.
Key Dates
| Date | Description |
|---|---|
| 2020-12-03 | Date of establishment for the Sujal Patel 2020 Children's Trust. |
| 2021-06-16 | Original filing date of the Schedule 13D by Sujal Patel. |
| 2023-03-01 | Filing date of Amendment No. 1 to the Schedule 13D. |
| 2025-02-21 | Date as of which 126,148,469 shares of Common Stock were outstanding, as reported in the Issuer's Form 10-K. |
| 2025-02-23 | Date the Power of Attorney was executed by Sujal Patel. |
| 2025-02-27 | Date the Issuer's Form 10-K was filed with the SEC, reporting outstanding shares as of February 21, 2025. |
| 2025-03-03 | Date of event requiring the filing of this statement; Sujal Patel was granted an option to purchase 650,000 shares of Common Stock. |
| 2025-03-05 | Signature date of this Amendment No. 2 to the Schedule 13D. |
Recommendation
holdKeywords
Nautilus Biotechnology, Sujal Patel, Schedule 13D, Beneficial Ownership, Insider Ownership, Common Stock, Stock Options, Biotechnology, SEC Filing, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.